Patent Term Application for HYMPAVZI (marstacimab-hncq), Patent No. 10,550,200 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0158

Patent Term Application for HYMPAVZI (marstacimab-hncq), Patent No. 10,550,200

Documents

Comments

Description

OPEN

Comment Period OpensJan 15, 2025

Comment Period ClosesJun 3, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI FR Doc: 2026-06481	Apr 3, 2026	--

CDER

Patent Term Application

Pfizer Inc.

HYMPAVZI (marstacimab-hncq)

Patent No. 10,550,200

OPEN